Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial

BACKGROUND: Delaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD) therapeutics. Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally invasive...

Descripción completa

Detalles Bibliográficos
Autores principales: Viña, José, Escudero, Joaquín, Baquero, Miquel, Cebrián, Mónica, Carbonell-Asíns, Juan Antonio, Muñoz, José Enrique, Satorres, Encarnación, Meléndez, Juan Carlos, Ferrer-Rebolleda, José, Cózar-Santiago, Mª del Puig, Santabárbara-Gómez, Jose Manuel, Jové, Mariona, Pamplona, Reinald, Tarazona-Santabalbina, Francisco José, Borrás, Consuelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635167/
https://www.ncbi.nlm.nih.gov/pubmed/36329553
http://dx.doi.org/10.1186/s13195-022-01097-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635167/
https://www.ncbi.nlm.nih.gov/pubmed/36329553
http://dx.doi.org/10.1186/s13195-022-01097-2

Ejemplares similares